# An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

> **NCT06991556** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 150 (estimated)

## Conditions studied

- Metastatic Hormone-sensitive Prostate Cancer

## Interventions

- **DRUG:** JSB462
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06991556
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2032-03-29
- **Final completion:** 2035-10-19
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06991556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06991556, "An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06991556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*